

Michael Trauner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3005934/publications.pdf>

Version: 2024-02-01

579
papers

42,624
citations

1980

101
h-index

3714

179
g-index

668
all docs

668
docs citations

668
times ranked

37838
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 261-280.	8.2	964
2	Detection of Various Microplastics in Human Stool. <i>Annals of Internal Medicine</i> , 2019, 171, 453-457.	2.0	939
3	Bile Salt Transporters: Molecular Characterization, Function, and Regulation. <i>Physiological Reviews</i> , 2003, 83, 633-671.	13.1	873
4	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2016, 375, 631-643.	13.9	817
5	The interaction of hepatic lipid and glucose metabolism in liver diseases. <i>Journal of Hepatology</i> , 2012, 56, 952-964.	1.8	728
6	Characterization of HULC, a Novel Gene With Striking Up-Regulation in Hepatocellular Carcinoma, as Noncoding RNA. <i>Gastroenterology</i> , 2007, 132, 330-342.	0.6	725
7	Molecular Pathogenesis of Cholestasis. <i>New England Journal of Medicine</i> , 1998, 339, 1217-1227.	13.9	719
8	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. <i>Annals of Internal Medicine</i> , 2020, 173, 350-361.	2.0	653
9	ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- α and PGC-1. <i>Nature Medicine</i> , 2011, 17, 1076-1085.	15.2	612
10	Bile acid receptors as targets for drug development. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 55-67.	8.2	565
11	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. <i>Gastroenterology</i> , 2004, 127, 261-274.	0.6	525
12	Adipose Triglyceride Lipase Contributes to Cancer-Associated Cachexia. <i>Science</i> , 2011, 333, 233-238.	6.0	475
13	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
14	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. <i>Hepatology</i> , 2017, 65, 350-362.	3.6	444
15	New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond. <i>Journal of Hepatology</i> , 2015, 62, S25-S37.	1.8	406
16	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2018, 13, 321-350.	9.6	387
17	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
18	Nonselective β_2 Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis. <i>Gastroenterology</i> , 2014, 146, 1680-1690.e1.	0.6	336

#	ARTICLE	IF	CITATIONS
19	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	8.2	330
20	Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. <i>Hepatology</i> , 2001, 33, 633-646.	3.6	324
21	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1084-1103.	1.8	311
22	Bile acid transporters and regulatory nuclear receptors in the liver and beyond. <i>Journal of Hepatology</i> , 2013, 58, 155-168.	1.8	304
23	Interference with Bile Salt Export Pump Function Is a Susceptibility Factor for Human Liver Injury in Drug Development. <i>Toxicological Sciences</i> , 2010, 118, 485-500.	1.4	302
24	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. <i>Hepatology</i> , 2005, 42, 420-430.	3.6	295
25	A New Xenobiotic-Induced Mouse Model of Sclerosing Cholangitis and Biliary Fibrosis. <i>American Journal of Pathology</i> , 2007, 171, 525-536.	1.9	293
26	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , 2020, 73, 26-39.	1.8	290
27	Role of Nuclear Receptors in the Adaptive Response to Bile Acids and Cholestasis: Pathogenetic and Therapeutic Considerations. <i>Molecular Pharmaceutics</i> , 2006, 3, 231-251.	2.3	288
28	The ART of decision making: Retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2261-2273.	3.6	288
29	Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangiocytes. <i>Gastroenterology</i> , 2002, 123, 1238-1251.	0.6	287
30	24-norUrsodeoxycholic Acid Is Superior to Ursodeoxycholic Acid in the Treatment of Sclerosing Cholangitis in Mdr2 (Abcb4) Knockout Mice. <i>Gastroenterology</i> , 2006, 130, 465-481.	0.6	282
31	Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2007, 1773, 283-308.	1.9	275
32	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , 2013, 62, 1634-1641.	6.1	275
33	Pathophysiological mechanisms of liver injury in COVID-19. <i>Liver International</i> , 2021, 41, 20-32.	1.9	273
34	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , 2013, 58, 911-921.	1.8	269
35	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , 2005, 129, 476-485.	0.6	268
36	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2003, 38, 717-727.	1.8	260

#	ARTICLE	IF	CITATIONS
37	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OST α -OST β in cholestasis in humans and rodents. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G1124-G1130.	1.6	255
38	Effects of Ursodeoxycholic and Cholic Acid Feeding on Hepatocellular Transporter Expression in Mouse Liver. <i>Gastroenterology</i> , 2001, 121, 170-183.	0.6	254
39	Bile Acids as Regulators of Hepatic Lipid and Glucose Metabolism. <i>Digestive Diseases</i> , 2010, 28, 220-224.	0.8	254
40	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. <i>Gastroenterology</i> , 2003, 125, 825-838.	0.6	252
41	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , 2016, 65, 692-699.	1.8	245
42	Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis. <i>Gastroenterology</i> , 2012, 142, 355-365.e4.	0.6	243
43	New molecular insights into the mechanisms of cholestasis. <i>Journal of Hepatology</i> , 2009, 51, 565-580.	1.8	241
44	Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. <i>Gastroenterology</i> , 2000, 118, 163-172.	0.6	240
45	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. <i>Journal of Hepatology</i> , 2015, 62, 1398-1404.	1.8	236
46	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , 2005, 129, 476-485.	0.6	235
47	Fatty liver and lipotoxicity. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 299-310.	1.2	232
48	Mdr2 (Abcb4) ^{-/-} mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. <i>Journal of Hepatology</i> , 2005, 43, 1045-1054.	1.8	228
49	Nuclear receptors in liver disease. <i>Hepatology</i> , 2011, 53, 1023-1034.	3.6	226
50	Sex-Specific Prevalence of Adenomas, Advanced Adenomas, and Colorectal Cancer in Individuals Undergoing Screening Colonoscopy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1352.	3.8	225
51	Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. <i>Journal of Hepatology</i> , 2003, 38, 419-425.	1.8	221
52	Inflammation-induced cholestasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, 946-959.	1.4	206
53	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2017, 67, 549-558.	1.8	202
54	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , 2014, 16, 972-981.	4.6	198

#	ARTICLE	IF	CITATIONS
55	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , 2019, 70, 1521-1530.	3.6	197
56	Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. <i>Journal of Hepatology</i> , 2016, 65, 856-858.	1.8	196
57	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , 2022, 71, 1006-1019.	6.1	195
58	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , 2016, 1, e000042.	2.0	194
59	Mechanisms of Disease: mechanisms and clinical implications of cholestasis in sepsis. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2006, 3, 574-585.	1.7	193
60	Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the <i>Mdr2</i> ^{-/-} (<i>Abcb4</i> ^{-/-}) mouse cholangiopathy model by promoting biliary HCO ₃ ⁻ output. <i>Hepatology</i> , 2011, 54, 1303-1312.	3.6	193
61	MDR3 (ABCB4) Defects: A Paradigm for the Genetics of Adult Cholestatic Syndromes. <i>Seminars in Liver Disease</i> , 2007, 27, 077-098.	1.8	188
62	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 788-801.	3.6	180
63	The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. <i>Hepatology</i> , 2017, 65, 1875-1890.	3.6	177
64	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. <i>Journal of Hepatology</i> , 2003, 39, 480-488.	1.8	171
65	Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 854-860.	1.3	168
66	New therapeutic concepts in bile acid transport and signaling for management of cholestasis. <i>Hepatology</i> , 2017, 65, 1393-1404.	3.6	167
67	Mechanisms of Cholestasis. <i>Clinics in Liver Disease</i> , 2008, 12, 1-26.	1.0	166
68	Lithocholic Acid Feeding Induces Segmental Bile Duct Obstruction and Destructive Cholangitis in Mice. <i>American Journal of Pathology</i> , 2006, 168, 410-422.	1.9	161
69	Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , 2012, 56, 1439-1447.	3.6	158
70	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
71	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. <i>Scientific Reports</i> , 2018, 8, 6220.	1.6	155
72	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-1 [±] /1 ² in the adaptive response to bile acids. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, G923-G932.	1.6	154

#	ARTICLE	IF	CITATIONS
73	Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts. <i>American Journal of Pathology</i> , 2009, 175, 2392-2405.	1.9	154
74	Liver Dysfunction and Phosphatidylinositol-3-Kinase Signalling in Early Sepsis: Experimental Studies in Rodent Models of Peritonitis. <i>PLoS Medicine</i> , 2012, 9, e1001338.	3.9	152
75	Molecular regulation of hepatocellular transport systems in cholestasis. <i>Journal of Hepatology</i> , 1999, 31, 165-178.	1.8	148
76	Spontaneous cholecysto- and hepatolithiasis in <i>Mdr2</i> ^{-/-} mice: A model for low phospholipid-associated cholelithiasis. <i>Hepatology</i> , 2004, 39, 117-128.	3.6	148
77	Molecular Regulation of Hepatobiliary Transport Systems. <i>Journal of Clinical Gastroenterology</i> , 2005, 39, S111-S124.	1.1	148
78	Coagulation parameters and major bleeding in critically ill patients with cirrhosis. <i>Hepatology</i> , 2016, 64, 556-568.	3.6	148
79	In vivo quantification of liver dialysis: Comparison of albumin dialysis and fractionated plasma separation. <i>Journal of Hepatology</i> , 2005, 43, 451-457.	1.8	146
80	Long-term Outcomes of Patients With Wilson Disease in a Large Austrian Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 683-689.	2.4	146
81	Nuclear receptors as therapeutic targets in cholestatic liver diseases. <i>British Journal of Pharmacology</i> , 2009, 156, 7-27.	2.7	143
82	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2016, 64, 674-681.	1.8	143
83	Alterations in Lipid Metabolism Mediate Inflammation, Fibrosis, and Proliferation in a Mouse Model of Chronic Cholestatic Liver Injury. <i>Gastroenterology</i> , 2012, 142, 140-151.e12.	0.6	139
84	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2014, 61, 1287-1296.	1.8	139
85	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in <i>Mdr2</i> ^{-/-} mice. <i>Hepatology</i> , 2009, 49, 1972-1981.	3.6	135
86	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , 2016, 63, 1357-1367.	3.6	133
87	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFTY score. <i>Journal of Hepatology</i> , 2022, 76, 353-363.	1.8	132
88	Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. <i>Hepatology</i> , 2013, 58, 2056-2069.	3.6	130
89	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , 2017, 66, 724-733.	1.8	130
90	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , 2014, 60, 1290-1303.	1.8	129

#	ARTICLE	IF	CITATIONS
91	The keratin cytoskeleton in liver diseases. <i>Journal of Pathology</i> , 2004, 204, 367-376.	2.1	121
92	Synthetic LXR agonist attenuates plaque formation in apoE ^{-/-} mice without inducing liver steatosis and hypertriglyceridemia. <i>Journal of Lipid Research</i> , 2009, 50, 312-326.	2.0	121
93	Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 432-450.	8.2	119
94	Hepatotoxicity of NONI juice: Report of two cases. <i>World Journal of Gastroenterology</i> , 2005, 11, 4758.	1.4	118
95	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 458, 511-523.	1.4	116
96	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 445-453.	3.7	116
97	Loss of CFTR Affects Biliary Epithelium Innate Immunity and Causes TLR4- and NF- κ B-Mediated Inflammatory Response in Mice. <i>Gastroenterology</i> , 2011, 141, 1498-1508.e5.	0.6	114
98	Hepatobiliary transporter expression in human hepatocellular carcinoma. <i>Liver International</i> , 2005, 25, 367-379.	1.9	112
99	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , 2020, 71, 1023-1036.	3.6	112
100	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , 2015, 35, 381-390.	1.9	111
101	Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth-III). <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 135-158.	1.0	111
102	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1323-1333.	1.9	106
103	The ART-strategy: Sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , 2014, 60, 118-126.	1.8	105
104	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. <i>Hepatology</i> , 2014, 59, 1972-1983.	3.6	105
105	Pathogenesis of primary sclerosing cholangitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 727-739.	1.0	104
106	Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2007, 27, 920-929.	1.9	103
107	Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. <i>Wiener Medizinische Wochenschrift</i> , 2008, 158, 542-548.	0.5	102
108	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102

#	ARTICLE	IF	CITATIONS
109	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 2224-2234.	3.6	101
110	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , 2021, 74, 133-147.	3.6	101
111	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , 2019, 68, 1099-1107.	6.1	100
112	Fxr ^{-/-} mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. <i>Journal of Lipid Research</i> , 2006, 47, 582-592.	2.0	98
113	Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. <i>Liver International</i> , 2012, 32, 845-851.	1.9	97
114	Gene Expression Profiling Unravels Cancer-Related Hepatic Molecular Signatures in Steatohepatitis but Not in Steatosis. <i>PLoS ONE</i> , 2012, 7, e46584.	1.1	97
115	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , 2021, 74, 819-828.	1.8	96
116	Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoteric Acid-enhanced MR Imaging. <i>Radiology</i> , 2015, 277, 104-113.	3.6	95
117	Molecular aspects of bile formation and cholestasis. <i>Trends in Molecular Medicine</i> , 2003, 9, 558-564.	3.5	94
118	Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G831-G841.	1.6	94
119	Nuclear Receptors as New Perspective for the Management of Liver Diseases. <i>Gastroenterology</i> , 2011, 140, 1120-1125.e12.	0.6	94
120	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography—a large single center experience. <i>Wiener Klinische Wochenschrift</i> , 2012, 124, 395-402.	1.0	93
121	The Arachidonic Acid Metabolome Serves as a Conserved Regulator of Cholesterol Metabolism. <i>Cell Metabolism</i> , 2014, 20, 787-798.	7.2	92
122	Farnesoid X receptor represses hepatic human APOA gene expression. <i>Journal of Clinical Investigation</i> , 2011, 121, 3724-3734.	3.9	92
123	Nuclear Receptor Regulation of the Adaptive Response of Bile Acid Transporters in Cholestasis. <i>Seminars in Liver Disease</i> , 2010, 30, 160-177.	1.8	90
124	Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 343-353.	1.4	89
125	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. <i>Metabolism: Clinical and Experimental</i> , 2014, 63, 1542-1552.	1.5	88
126	Liver Injury and Failure in Critical Illness. <i>Hepatology</i> , 2019, 70, 2204-2215.	3.6	88

#	ARTICLE	IF	CITATIONS
127	Nuclear Receptors as Drug Targets in Cholestatic Liver Diseases. <i>Clinics in Liver Disease</i> , 2013, 17, 161-189.	1.0	87
128	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. <i>Archives of Toxicology</i> , 2015, 89, 2089-2103.	1.9	86
129	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , 2019, 105, 102328.	3.0	86
130	Hepatic steatosis in Wilson disease – Role of copper and PNPLA3 mutations. <i>Journal of Hepatology</i> , 2015, 63, 156-163.	1.8	85
131	Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. <i>Journal of Hepatology</i> , 2013, 58, 1201-1208.	1.8	84
132	Novel therapeutic targets for cholestatic and fatty liver disease. <i>Gut</i> , 2022, 71, 194-209.	6.1	84
133	EASL Clinical Practice Guidelines on sclerosing cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 761-806.	1.8	84
134	Curcumin improves sclerosing cholangitis in Mdr2 ^{-/-} mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. <i>Gut</i> , 2010, 59, 521-530.	6.1	83
135	Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. <i>Hepatology</i> , 2019, 69, 258-269.	3.6	83
136	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019, 157, 705-719.e18.	0.6	82
137	Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. <i>Toxicology Letters</i> , 2014, 228, 56-66.	0.4	81
138	Oncosis represents the main type of cell death in mouse models of cholestasis. <i>Journal of Hepatology</i> , 2005, 42, 378-385.	1.8	80
139	Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. <i>International Journal of Cancer</i> , 2012, 130, 2232-2239.	2.3	80
140	Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. <i>Hepatology</i> , 2014, 59, 858-869.	3.6	80
141	Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2016, 36, 069-086.	1.8	80
142	Cystic Fibrosis-related Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 65, 443-448.	0.9	80
143	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. , 2010, 126, 228-243.		79
144	Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. <i>Hepatology</i> , 2007, 46, 776-784.	3.6	77

#	ARTICLE	IF	CITATIONS
145	Sedation in Screening Colonoscopy: Impact on Quality Indicators And Complications. American Journal of Gastroenterology, 2012, 107, 1837-1848.	0.2	77
146	Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 867-878.	1.8	75
147	Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. Hepatology, 2012, 56, 270-280.	3.6	75
148	Hypoxic liver injury and cholestasis in critically ill patients. Current Opinion in Critical Care, 2013, 19, 128-132.	1.6	75
149	A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. Psychosomatic Medicine, 2018, 80, 698-709.	1.3	75
150	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. Journal of the American College of Cardiology, 2012, 59, 585-592.	1.2	74
151	Bile acids induce arrhythmias in human atrial myocardium—implications for altered serum bile acid composition in patients with atrial fibrillation. Heart, 2013, 99, 1685-1692.	1.2	73
152	The liver in sepsis. Current Opinion in Critical Care, 2013, 19, 123-127.	1.6	73
153	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. Transplant International, 2016, 29, 999-1007.	0.8	73
154	Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. Journal of Hepatology, 1997, 27, 163-169.	1.8	72
155	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. Liver International, 2015, 35, 2121-2128.	1.9	72
156	Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. Immunity, 2019, 51, 1074-1087.e9.	6.6	72
157	Signal Transducer and Activator of Transcription 3 Protects From Liver Injury and Fibrosis in a Mouse Model of Sclerosing Cholangitis. Gastroenterology, 2010, 138, 2499-2508.	0.6	71
158	Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. Trends in Endocrinology and Metabolism, 2014, 25, 576-585.	3.1	71
159	Inflammatory Bowel Disease Alters Intestinal Bile Acid Transporter Expression. Drug Metabolism and Disposition, 2014, 42, 1423-1431.	1.7	70
160	Noninvasive Differentiation of Simple Steatosis and Steatohepatitis by Using Gadoteric Acid—enhanced MR Imaging in Patients with Nonalcoholic Fatty Liver Disease: A Proof-of-Concept Study. Radiology, 2014, 271, 739-747.	3.6	70
161	Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. Hepatology, 1998, 28, 1081-1087.	3.6	68
162	Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. Hepatology, 2012, 56, 2297-2304.	3.6	68

#	ARTICLE	IF	CITATIONS
163	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00131.	1.3	68
164	Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 77, 918-930.	1.8	68
165	Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 289, G798-G805.	1.6	67
166	Acid-base disorders in liver disease. <i>Journal of Hepatology</i> , 2017, 67, 1062-1073.	1.8	67
167	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , 2019, 25, 5897-5917.	1.4	67
168	Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. <i>American Journal of Physiology - Renal Physiology</i> , 2002, 282, G184-G191.	1.6	66
169	Role of adipose tissue in methionine- ϵ -choline-deficient model of non-alcoholic steatohepatitis (NASH). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 959-970.	1.8	66
170	Fibrosis in Autoimmune and Cholestatic Liver Disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 245-258.	1.0	65
171	The Role of Canalicular ABC Transporters in Cholestasis. <i>Drug Metabolism and Disposition</i> , 2014, 42, 546-560.	1.7	65
172	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2552-2560.e10.	2.4	65
173	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , 2021, 41, 2249-2268.	1.9	64
174	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	1.8	64
175	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi α -Z Variant of AAT (Pi α -MZ vs Tj ETQq1.1). <i>Journal of Hepatology</i> , 2014, 61, 1073-1081.	0.6	63
176	miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. <i>Diabetes</i> , 2018, 67, 2541-2553.	0.3	60
177	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021, 160, 1608-1619.e13.	0.6	60
178	Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH. <i>Journal of Hepatology</i> , 2022, 77, 1373-1385.	1.8	60
179	Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. <i>Cut</i> , 2019, 68, 522-532.	6.1	59
180	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	1.8	59

#	ARTICLE	IF	CITATIONS
181	PNPLA3 expression and its impact on the liver: current perspectives. <i>Hepatic Medicine: Evidence and Research</i> , 2017, Volume 9, 55-66.	0.9	58
182	Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal—a Case Series. <i>Obesity Surgery</i> , 2018, 28, 812-819.	1.1	58
183	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 781-793.	3.7	58
184	Molecular mechanisms of cholestasis. <i>Wiener Medizinische Wochenschrift</i> , 2006, 156, 380-385.	0.5	57
185	Portal Pressure Predicts Outcome and Safety of Antiviral Therapy in Cirrhotic Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 602-608.e1.	2.4	57
186	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	2.4	57
187	Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. <i>Journal of Hepatology</i> , 2020, 73, 651-663.	1.8	57
188	Will we ever model PSC? — It's hard to be a PSC model! <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2011, 35, 792-804.	0.7	56
189	Current treatment of non-alcoholic fatty liver disease. <i>Journal of Internal Medicine</i> , 2022, 292, 190-204.	2.7	56
190	Bile Acid-Mediated Control of Liver Triglycerides. <i>Seminars in Liver Disease</i> , 2013, 33, 330-342.	1.8	55
191	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. <i>Journal of Hepatology</i> , 2015, 62, 871-878.	1.8	55
192	Renal replacement therapy in critically ill liver cirrhotic patients—outcome and clinical implications. <i>Liver International</i> , 2017, 37, 843-850.	1.9	55
193	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. <i>United European Gastroenterology Journal</i> , 2019, 7, 1113-1123.	1.6	55
194	Proton Pump Inhibitor Intake neither Predisposes to Spontaneous Bacterial Peritonitis or Other Infections nor Increases Mortality in Patients with Cirrhosis and Ascites. <i>PLoS ONE</i> , 2014, 9, e110503.	1.1	55
195	Common genetic variation in vitamin D metabolism is associated with liver stiffness. <i>Hepatology</i> , 2012, 56, 1883-1891.	3.6	54
196	Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 646-659.	1.9	54
197	A little orphan runs to fat: The orphan receptor small heterodimer partner as a key player in the regulation of hepatic lipid metabolism. <i>Hepatology</i> , 2007, 46, 1-5.	3.6	53
198	Colesevelam attenuates cholestatic liver and bile duct injury in <i>Mdr2</i> ^{−/−} mice by modulating composition, signalling and excretion of faecal bile acids. <i>Gut</i> , 2018, 67, 1683-1691.	6.1	53

#	ARTICLE	IF	CITATIONS
199	Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. <i>Toxicology Letters</i> , 2014, 224, 186-195.	0.4	52
200	Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes. <i>Cell Systems</i> , 2018, 6, 709-721.e6.	2.9	52
201	Validated Comprehensive Analytical Method for Quantification of Coenzyme A Activated Compounds in Biological Tissues by Online Solid-Phase Extraction LC/MS/MS. <i>Analytical Chemistry</i> , 2008, 80, 5736-5742.	3.2	51
202	Metabolic preconditioning protects BSEP/ABCB11 ^{-/-} mice against cholestatic liver injury. <i>Journal of Hepatology</i> , 2017, 66, 95-101.	1.8	51
203	Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. <i>Liver International</i> , 2018, 38, 1028-1035.	1.9	51
204	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , 2021, 70, 1758-1767.	6.1	51
205	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 634-646.	1.8	51
206	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , 2020, , .	0.2	51
207	Removal of Bile Acids by Two Different Extracorporeal Liver Support Systems in Acute-on-Chronic Liver Failure. <i>ASAIO Journal</i> , 2007, 53, 187-193.	0.9	50
208	Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. <i>Atherosclerosis</i> , 2010, 209, 178-183.	0.4	50
209	Clinical application of transcriptional activators of bile salt transporters. <i>Molecular Aspects of Medicine</i> , 2014, 37, 57-76.	2.7	50
210	Na ⁺ -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. <i>Hepatology</i> , 2018, 68, 1057-1069.	3.6	50
211	Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1243-1262.	1.9	50
212	Circulating bile acids predict outcome in critically ill patients. <i>Annals of Intensive Care</i> , 2017, 7, 48.	2.2	49
213	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2017, 5, 987-996.	1.6	49
214	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. <i>Oncotarget</i> , 2017, 8, 46234-46248.	0.8	49
215	Bile acids in regulation of inflammation and immunity: friend or foe?. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 25-31.	0.4	49
216	Endoscopic intracorporeal laser lithotripsy of difficult common bile duct stones with a stone-recognition pulsed dye laser system. <i>Gastrointestinal Endoscopy</i> , 1995, 42, 416-419.	0.5	48

#	ARTICLE	IF	CITATIONS
217	Disruption of the growth hormone-Signal transducer and activator of transcription 5-Insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. <i>Hepatology</i> , 2010, 51, 1319-1326.	3.6	48
218	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 57, 492-498.	1.8	48
219	Bile Acid-Induced Cholemic Nephropathy. <i>Digestive Diseases</i> , 2015, 33, 367-375.	0.8	48
220	Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. <i>Obesity Surgery</i> , 2016, 26, 2425-2432.	1.1	48
221	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 203-217.	4.2	48
222	Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. <i>Liver International</i> , 2017, 37, 224-231.	1.9	47
223	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , 2019, 39, 2374-2385.	1.9	47
224	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. <i>Journal of Hepatology</i> , 2020, 72, 1122-1131.	1.8	47
225	Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. <i>Journal of Hepatology</i> , 2003, 38, 387-394.	1.8	46
226	Cystic Fibrosis Related Liver Disease—Another Black Box in Hepatology. <i>International Journal of Molecular Sciences</i> , 2014, 15, 13529-13549.	1.8	46
227	Recent advances in understanding and managing cholestasis. <i>F1000Research</i> , 2016, 5, 705.	0.8	46
228	Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide—results of a real-world study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 144-154.	1.9	46
229	The Importance of Serum Bile Acid Level Analysis and Treatment With Ursodeoxycholic Acid in Intrahepatic Cholestasis of Pregnancy. <i>Archives of Dermatology</i> , 2007, 143, 757-62.	1.7	45
230	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. <i>EBioMedicine</i> , 2016, 11, 58-67.	2.7	45
231	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 194-204.	1.9	45
232	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , 2021, 73, 1275-1289.	3.6	45
233	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis. <i>Hepatology</i> , 2022, 75, 1235-1246.	3.6	45
234	Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. <i>Hepatology</i> , 2022, 76, 1563-1575.	3.6	45

#	ARTICLE	IF	CITATIONS
235	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. <i>Journal of Hepatology</i> , 2017, 67, 110-119.	1.8	44
236	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 8-15.	1.0	44
237	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. <i>Journal of Hepatology</i> , 2019, 71, 986-991.	1.8	44
238	Bile Acid-Induced Mallory Body Formation in Drug-Primed Mouse Liver. <i>American Journal of Pathology</i> , 2002, 161, 2019-2026.	1.9	43
239	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 200-219.	1.0	43
240	von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. <i>Journal of Hepatology</i> , 2014, 61, 544-549.	1.8	43
241	From the origin of NASH to the future of metabolic fatty liver disease. <i>Gut</i> , 2021, 70, 1570-1579.	6.1	43
242	Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis. <i>Annals of Hepatology</i> , 2005, 4, 77-99.	0.6	42
243	Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography – The Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , 2010, 208, 564-571.	0.4	42
244	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , 2016, 30, 1039-1047.	1.0	42
245	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2015, 61, 85-90.	0.9	41
246	Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 385-394.	2.3	41
247	Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. <i>Digestive Diseases</i> , 2016, 34, 580-588.	0.8	41
248	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 446-455.	1.0	41
249	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. <i>Genes</i> , 2021, 12, 645.	1.0	41
250	Cytokeratins as Targets for Bile Acid-Induced Toxicity. <i>American Journal of Pathology</i> , 2002, 160, 491-499.	1.9	40
251	Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. <i>Hepatology</i> , 2005, 41, 470-477.	3.6	40
252	The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. <i>Obesity Surgery</i> , 2016, 26, 2204-2212.	1.1	40

#	ARTICLE	IF	CITATIONS
253	E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration. <i>Developmental Cell</i> , 2020, 52, 335-349.e7.	3.1	40
254	Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the <i>Abcb4</i> mouse model. <i>World Journal of Hepatology</i> , 2016, 8, 401.	0.8	40
255	Down-regulation of the Na ⁺ /taurocholate cotransporting polypeptide during pregnancy in the rat. <i>Journal of Hepatology</i> , 2003, 38, 148-155.	1.8	39
256	Low vitamin D levels are associated with impaired virologic response to PEGIFNα+αSRBV therapy in HIV+hepatitis C virus coinfecting patients. <i>Aids</i> , 2013, 27, 227-232.	1.0	39
257	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , 2014, 60, 1135-1142.	1.8	39
258	Indications for liver transplantation in adults. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 679-690.	1.0	39
259	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , 2018, 8, 9372.	1.6	39
260	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , 2019, 39, 127-135.	1.9	39
261	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1362-1373.e6.	2.4	39
262	The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. <i>Laboratory Investigation</i> , 2010, 90, 844-852.	1.7	38
263	Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. <i>Gut</i> , 2011, 60, 387-396.	6.1	38
264	Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. <i>Laboratory Investigation</i> , 2012, 92, 857-867.	1.7	38
265	Potential of Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. <i>Digestive Diseases</i> , 2015, 33, 433-439.	0.8	38
266	Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-κB: New insights into hepatic inflammation. <i>Hepatology</i> , 2008, 48, 1383-1386.	3.6	37
267	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1657-1665.	1.4	37
268	1,25-(OH) ₂ -vitamin D ₃ prevents activation of hepatic stellate cells <i>in vitro</i> and ameliorates inflammatory liver damage but not fibrosis in the <i>Abcb4</i> model. <i>Biochemical and Biophysical Research Communications</i> , 2015, 459, 227-233.	1.0	37
269	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , 2021, 9, 60.	1.4	37
270	No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. <i>American Journal of Gastroenterology</i> , 2001, 96, 2286-2287.	0.2	36

#	ARTICLE	IF	CITATIONS
271	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. <i>Hepatology</i> , 2010, 52, 1758-1768.	3.6	36
272	Fibrate treatment for primary biliary cirrhosis. <i>Current Opinion in Gastroenterology</i> , 2014, 30, 279-286.	1.0	36
273	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , 2021, 41, 2159-2170.	1.9	36
274	Health-related quality of life and severity of fatigue in HIV/HCV coinfected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , 2014, 34, 69-77.	1.9	35
275	Ultra-high field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis. <i>Liver International</i> , 2017, 37, 1544-1553.	1.9	35
276	Liver Transplantation. <i>Investigative Radiology</i> , 2012, 47, 353-358.	3.5	34
277	Assessment of Orthotopic Liver Transplant Graft Survival on Gadoteric Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. <i>Investigative Radiology</i> , 2016, 51, 728-734.	3.5	34
278	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , 2017, 8, e3135-e3135.	2.7	34
279	Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. <i>Liver International</i> , 2009, 29, 1516-1520.	1.9	33
280	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. <i>Digestive Diseases</i> , 2015, 33, 598-607.	0.8	33
281	Fine-tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. <i>Hepatology</i> , 2019, 69, 699-716.	3.6	33
282	Pathophysiological Role of Poly(ADP-Ribose) Polymerase (PARP) Activation during Acetaminophen-Induced Liver Cell Necrosis in Mice. <i>Toxicological Sciences</i> , 2005, 84, 201-208.	1.4	32
283	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. <i>Journal of Hepatology</i> , 2006, 44, 243-245.	1.8	32
284	Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. <i>Journal of Hepatology</i> , 2011, 55, 876-884.	1.8	32
285	The PPAR α agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2013, 1831, 1555-1565.	1.2	32
286	Revisiting liver disease progression in HIV/HCV coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , 2015, 35, 876-885.	1.9	32
287	Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , 2017, 35, 282-287.	0.8	32
288	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0233781.	1.1	32

#	ARTICLE	IF	CITATIONS
289	Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. <i>Liver International</i> , 2009, 29, 1316-1325.	1.9	31
290	Incidence and mortality trends for biliary tract cancers in Austria. <i>Liver International</i> , 2014, 34, 1102-1108.	1.9	31
291	Therapy of Primary Sclerosing Cholangitis - Today and Tomorrow. <i>Digestive Diseases</i> , 2015, 33, 149-163.	0.8	31
292	Trends in quality of screening colonoscopy in Austria. <i>Endoscopy</i> , 2016, 48, 1102-1109.	1.0	31
293	Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. <i>Digestive Diseases</i> , 2017, 35, 288-292.	0.8	31
294	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , 2018, 38, 1427-1436.	1.9	31
295	Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. <i>Journal of Hepatology</i> , 2022, 77, 71-83.	1.8	31
296	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2004, 20, 220-230.	1.0	30
297	Outcomes after placement of a SXLLE oesophageal stent for refractory variceal bleeding: A national multicentre study. <i>Liver International</i> , 2019, 39, 290-298.	1.9	30
298	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , 2020, 8, 321-331.	1.6	30
299	Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. <i>British Journal of Cancer</i> , 2016, 115, 1421-1429.	2.9	29
300	Vitamin D3 Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial. <i>Obesity Surgery</i> , 2017, 27, 1196-1207.	1.1	29
301	The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease. <i>Hepatology</i> , 2020, 72, 1117-1126.	3.6	29
302	New Insights into Autoimmune Cholangitis through Animal Models. <i>Digestive Diseases</i> , 2010, 28, 99-104.	0.8	28
303	Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. <i>Journal of Hepatology</i> , 2014, 60, 1187-1193.	1.8	28
304	Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. <i>Annals of Intensive Care</i> , 2016, 6, 61.	2.2	28
305	Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. <i>United European Gastroenterology Journal</i> , 2017, 5, 104-110.	1.6	28
306	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , 2017, 49, 1360-1367.	0.4	28

#	ARTICLE	IF	CITATIONS
307	Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. <i>Journal of Trace Elements in Medicine and Biology</i> , 2017, 39, 100-107.	1.5	28
308	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , 2018, 38, 1036-1044.	1.9	28
309	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. <i>Liver International</i> , 2018, 38, 523-531.	1.9	28
310	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	6.1	28
311	Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , 2021, 41, 461-475.	1.8	28
312	Nitric oxide and guanosine 3',5'-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. <i>Hepatology</i> , 1998, 28, 1621-1628.	3.6	27
313	A Prospective Evaluation of Pulmonary, Systemic and Hepatic Haemodynamics in HIV-HCV-Coinfected Patients before and after Antiviral Therapy with Pegylated Interferon and Ribavirin. <i>Antiviral Therapy</i> , 2012, 17, 1327-1334.	0.6	27
314	Application of localized 31P MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. <i>European Radiology</i> , 2014, 24, 1602-1609.	2.3	27
315	Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. <i>Hepatology</i> , 2015, 61, 613-626.	3.6	27
316	Autophagy induced by exogenous bile acids is therapeutic in a model of α -1-AT deficiency liver disease. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G156-G165.	1.6	27
317	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. <i>Journal of Hepatology</i> , 2018, 69, 368-377.	1.8	27
318	NorUDCA promotes degradation of α -1-antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. <i>PLoS ONE</i> , 2018, 13, e0200897.	1.1	27
319	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. <i>Journal of Lipid Research</i> , 2019, 60, 1284-1292.	2.0	27
320	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , 2020, 40, 2797-2807.	1.9	27
321	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , 2021, 41, 799-809.	1.9	27
322	Open-label phase III study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 441-451.	1.0	27
323	Primary Sclerosing Cholangitis: New Approaches to Diagnosis, Surveillance and Treatment. <i>Digestive Diseases</i> , 2012, 30, 39-47.	0.8	26
324	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGFA expression in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2013, 1, 265-275.	1.6	26

#	ARTICLE	IF	CITATIONS
325	PNPLA3 I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells. <i>Hepatology Communications</i> , 2019, 3, 1191-1204.	2.0	26
326	The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. <i>Hepatology</i> , 2020, 72, 584-594.	3.6	26
327	COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center. <i>Pathology Research and Practice</i> , 2021, 217, 153305.	1.0	26
328	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD. <i>Journal of Hepatology</i> , 2022, 76, 1090-1099.	1.8	26
329	Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. <i>Journal of Hepatology</i> , 1998, 28, 812-819.	1.8	25
330	Hepatic transport systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S105-S112.	1.4	25
331	Evolving concepts in primary sclerosing cholangitis. <i>Liver International</i> , 2012, 32, 352-369.	1.9	25
332	High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. <i>Endoscopy</i> , 2015, 47, 207-216.	1.0	25
333	Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 496-502.	0.5	25
334	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e251-e266.	2.4	25
335	Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like) Tj ETQq1 1 0.784314 rgBT /Ove 2022, 75, 125-139.	3.6	25
336	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 10054-10068.	0.8	25
337	Targeting Nuclear Bile Acid Receptors for Liver Disease. <i>Digestive Diseases</i> , 2011, 29, 98-102.	0.8	24
338	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: Possible implications for sclerosing cholangitis. <i>Journal of Hepatology</i> , 2013, 58, 750-756.	1.8	24
339	Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. <i>Annals of Intensive Care</i> , 2018, 8, 48.	2.2	24
340	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. <i>Cells</i> , 2021, 10, 2516.	1.8	24
341	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0181878.	1.1	24
342	Extrahepatic cholestasis downregulates Oatp1 by TNF- α signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver. <i>Liver International</i> , 2007, 27, 1056-1065.	1.9	23

#	ARTICLE	IF	CITATIONS
343	Role of hepatic phospholipids in development of liver injury in <i>Mdr2</i> (<i>Abcb4</i>) knockout mice. <i>Liver International</i> , 2008, 28, 948-958.	1.9	23
344	Performance of 2-D Shear Wave Elastography in Liver Fibrosis Assessment Compared with Serologic Tests and Transient Elastography in Clinical Routine. <i>Ultrasound in Medicine and Biology</i> , 2015, 41, 2340-2349.	0.7	23
345	Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?. <i>Endoscopy</i> , 2015, 47, 898-902.	1.0	23
346	The role of TIPS in the management of liver transplant candidates. <i>United European Gastroenterology Journal</i> , 2017, 5, 1100-1107.	1.6	23
347	Liver disease in adults with α_1 -antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , 2018, 6, 710-718.	1.6	23
348	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , 2019, 51, 1144-1151.	0.4	23
349	Nuclear receptors in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166235.	1.8	23
350	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , 2015, 10, e0143429.	1.1	23
351	Maternal cholestasis does not affect the ontogenic pattern of expression of the Na ⁺ /Taurocholate cotransporting polypeptide (<i>ntcp</i>) in the fetal and neonatal rat liver. <i>Hepatology</i> , 1998, 28, 789-795.	3.6	22
352	Clinical Hepatotoxicity. Regulation and Treatment with Inducers of Transport and Cofactors. <i>Molecular Pharmaceutics</i> , 2007, 4, 895-910.	2.3	22
353	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. <i>PLoS ONE</i> , 2019, 14, e0216677.	1.1	22
354	High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. <i>United European Gastroenterology Journal</i> , 2019, 7, 507-516.	1.6	22
355	Optical control of the nuclear bile acid receptor FXR with a photohormone. <i>Chemical Science</i> , 2020, 11, 429-434.	3.7	22
356	Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 369-377.	2.2	22
357	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-to-chronic liver failure. <i>United European Gastroenterology Journal</i> , 2021, 9, 427-437.	1.6	22
358	Intra-hepatic haematoma complicating transjugular intrahepatic portosystemic shunt for Budd-Chiari syndrome associated with anti-phospholipid antibodies, aplastic anaemia and chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 813-816.	0.8	21
359	Successful conservative management of acute hepatic failure following exertional heatstroke. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 1135-1139.	0.8	21
360	Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. <i>Journal of Human Genetics</i> , 2012, 57, 564-567.	1.1	21

#	ARTICLE	IF	CITATIONS
361	Endoscopists with low adenoma detection rates benefit from high-definition endoscopy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2015, 29, 466-473.	1.3	21
362	Adiponectin regulates AQP3 via PPAR α in human hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 51-54.	1.0	21
363	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1415-1426.	1.9	21
364	Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. <i>Liver International</i> , 2020, 40, 1098-1110.	1.9	21
365	Serum alkaline phosphatase levels accurately reflect cholestasis in mice. <i>Hepatology</i> , 2015, 62, 981-983.	3.6	20
366	Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. <i>BMC Medicine</i> , 2016, 14, 107.	2.3	20
367	Single-sex infection with female <i>Schistosoma mansoni</i> cercariae mitigates hepatic fibrosis after secondary infection. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005595.	1.3	20
368	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding – A two decades experience. <i>PLoS ONE</i> , 2018, 13, e0189414.	1.1	20
369	Impact of <i>HSD17B13</i> rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , 2020, 40, 393-404.	1.9	20
370	Soluble guanylyl cyclase stimulation and phosphodiesterase α 5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. <i>United European Gastroenterology Journal</i> , 2020, 8, 1174-1185.	1.6	20
371	Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 1620-1633.	1.9	20
372	24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation. <i>Journal of Hepatology</i> , 2021, 75, 1164-1176.	1.8	20
373	The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: Hype or hope?. <i>Hepatology</i> , 2004, 40, 260-263.	3.6	19
374	The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C23-ester Glucuronide in the Liver. <i>Journal of Biological Chemistry</i> , 2010, 285, 1113-1121.	1.6	19
375	Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats. <i>Liver International</i> , 2013, 33, 283-293.	1.9	19
376	Alterations of Canalicular ATP-Binding Cassette Transporter Expression in Drug-Induced Liver Injury. <i>Digestion</i> , 2014, 90, 81-88.	1.2	19
377	Phosphatidylcholine contributes to in vivo ^{31}P MRS signal from the human liver. <i>European Radiology</i> , 2015, 25, 2059-2066.	2.3	19
378	Management of portal hypertension before and after liver transplantation. <i>Liver Transplantation</i> , 2018, 24, 112-121.	1.3	19

#	ARTICLE	IF	CITATIONS
379	Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl4 mouse model. <i>Laboratory Investigation</i> , 2019, 99, 1906-1917.	1.7	19
380	Impact of adenoma detection rate on detection of advanced adenomas and endoscopic adverse events in a study of over 200,000 screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , 2020, 91, 135-141.	0.5	19
381	Noninvasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , 2020, 40, 894-904.	1.9	19
382	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , 2022, 4, 100513.	2.6	19
383	An In Silico Classification Model for Putative ABCC2 Substrates. <i>Molecular Informatics</i> , 2012, 31, 547-553.	1.4	18
384	Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies. <i>Digestive Diseases</i> , 2014, 32, 631-636.	0.8	18
385	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease. <i>Medicine (United States)</i> , 2016, 95, e4061.	0.4	18
386	The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. <i>European Radiology</i> , 2019, 29, 1048-1058.	2.3	18
387	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2019, 7, 850-858.	1.6	18
388	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. <i>Hepatology</i> , 2020, 71, 1750-1765.	3.6	18
389	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , 2020, 55, 533-542.	2.3	18
390	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , 2022, 75, 610-622.	3.6	18
391	Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. <i>Hepatology</i> , 1998, 28, 646-654.	3.6	17
392	When bile ducts say NO: The good, the bad, and the ugly. <i>Gastroenterology</i> , 2003, 124, 847-851.	0.6	17
393	Fatal hemobilia resulting from an iatrogenic arteriobiliary fistula as a rare complication of transjugular liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 83-86.	0.8	17
394	Xenobiotic-induced liver injury and fibrosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 571-580.	1.5	17
395	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 184-190.	1.4	17
396	The Addition of C-reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease Sodium Improves Prediction of Waitlist Mortality. <i>Hepatology</i> , 2021, 74, 1533-1545.	3.6	17

#	ARTICLE	IF	CITATIONS
397	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , 2013, 33, 561-568.	1.9	16
398	Role of <i>FDFT1</i> polymorphism for fibrosis progression in patients with chronic hepatitis C. <i>Liver International</i> , 2014, 34, 388-395.	1.9	16
399	Impact of higher-order heme degradation products on hepatic function and hemodynamics. <i>Journal of Hepatology</i> , 2017, 67, 272-281.	1.8	16
400	Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. <i>United European Gastroenterology Journal</i> , 2018, 6, 1049-1055.	1.6	16
401	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , 2019, 49, 201-211.	1.8	16
402	Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors. <i>Gut</i> , 2021, 70, 1309-1317.	6.1	16
403	COVID-19 Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , 2021, 5, 1660-1675.	2.0	16
404	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , 2021, 16, e0256544.	1.1	16
405	Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect. <i>PLoS ONE</i> , 2016, 11, e0148210.	1.1	16
406	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 2707-2714.	1.0	15
407	A Greater Proportion of Liver Transplant Candidates Have Colorectal Neoplasia Than in the Healthy Screening Population. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 956-962.	2.4	15
408	Liver Capsule: FXR agonists against liver disease. <i>Hepatology</i> , 2016, 64, 1773-1773.	3.6	15
409	FXR controls CHOP expression in steatohepatitis. <i>FEBS Letters</i> , 2017, 591, 3360-3368.	1.3	15
410	AQP3 is regulated by PPAR β and JNK in hepatic stellate cells carrying PNPLA3 I148M. <i>Scientific Reports</i> , 2017, 7, 14661.	1.6	15
411	Resection rates and safety profile of cold vs. hot snare polypectomy in polyps sized 5–10 mm and 11–20 mm. <i>Digestive and Liver Disease</i> , 2019, 51, 536-541.	0.4	15
412	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , 2020, 132, 1-11.	1.0	15
413	Loss of bile salt export pump aggravates lipopolysaccharide-induced liver injury in mice due to impaired hepatic endotoxin clearance. <i>Hepatology</i> , 2022, 75, 1095-1109.	3.6	15
414	Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. <i>Liver International</i> , 2022, 42, 1297-1307.	1.9	15

#	ARTICLE	IF	CITATIONS
415	Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test. <i>Medical Oncology</i> , 2014, 31, 151.	1.2	14
416	Pharmacological correction of misfolding of ABC proteins. <i>Drug Discovery Today: Technologies</i> , 2014, 12, e87-e94.	4.0	14
417	Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. <i>Annals of Intensive Care</i> , 2015, 5, 47.	2.2	14
418	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance. <i>Investigative Radiology</i> , 2017, 52, 462-469.	3.5	14
419	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 105-114.	1.0	14
420	Thyroid hormone receptor β 1 stimulates ABCB4 to increase biliary phosphatidylcholine excretion in mice. <i>Journal of Lipid Research</i> , 2018, 59, 1610-1619.	2.0	14
421	Waitlist mortality and post-transplant survival in patients with cholestatic liver disease – Impact of changes in allocation policy. <i>Hpb</i> , 2018, 20, 916-924.	0.1	14
422	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , 2020, 40, 1713-1724.	1.9	14
423	Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. <i>Liver International</i> , 2020, 40, 1366-1377.	1.9	14
424	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , 2020, 40, 787-796.	1.9	14
425	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2021, 73, 1105-1116.	3.6	14
426	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. <i>Hepatology International</i> , 2021, 15, 922-933.	1.9	14
427	Ursodeoxycholic acid prevents ventricular conduction slowing and arrhythmia by restoring T-type calcium current in fetuses during cholestasis. <i>PLoS ONE</i> , 2017, 12, e0183167.	1.1	14
428	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2001, 17, 242-256.	1.0	13
429	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2003, 19, 216-231.	1.0	13
430	Hepatocyte nuclear factor-4 β and bile acids regulate human concentrative nucleoside transporter-1 gene expression. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G936-G947.	1.6	13
431	Imbalance of pro- and antifibrogenic genes and bile duct injury in murine <i>Schistosoma mansoni</i> infection-induced liver fibrosis. <i>Tropical Medicine and International Health</i> , 2009, 14, 1418-1425.	1.0	13
432	When lightning strikes twice: The plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2009, 50, 633-635.	1.8	13

#	ARTICLE	IF	CITATIONS
433	Bile Acids as Modulators of Gut Microbiota Linking Dietary Habits and Inflammatory Bowel Disease: A Potentially Dangerous Liaison. <i>Gastroenterology</i> , 2013, 144, 844-846.	0.6	13
434	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 1-8.	0.6	13
435	Surveillance colonoscopy in Austria: Are we following the guidelines?. <i>Endoscopy</i> , 2018, 50, 119-127.	1.0	13
436	Prevalence of <i>Helicobacter pylori</i> and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. <i>PLoS ONE</i> , 2018, 13, e0197695.	1.1	13
437	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , 2019, 131, 395-403.	1.0	13
438	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson's Disease. <i>JHEP Reports</i> , 2019, 1, 2-8.	2.6	13
439	High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitis. <i>Liver International</i> , 2019, 39, 640-645.	1.9	13
440	PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8711.	1.8	13
441	NCOR1 Orchestrates Transcriptional Landscapes and Effector Functions of CD4+ T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 579.	2.2	13
442	Hepatocyte specific expression of an oncogenic variant of β -catenin results in cholestatic liver disease. <i>Oncotarget</i> , 2016, 7, 86985-86998.	0.8	13
443	Hepatobiliary Transporter Expression in Intercellular Adhesion Molecule 1 Knockout and Fas Receptor-Deficient Mice after Common Bile Duct Ligation Is Independent of the Degree of Inflammation and Oxidative Stress. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1694-1699.	1.7	12
444	Ischemia and Cholestasis: More Than (Just) the Bile Ducts!. <i>Transplantation</i> , 2008, 85, 1083-1085.	0.5	12
445	The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 328.	0.7	12
446	Molecular Mechanism of Taurocholate Transport by the Bile Salt Export Pump, an ABC Transporter Associated with Intrahepatic Cholestasis. <i>Molecular Pharmacology</i> , 2017, 92, 401-413.	1.0	12
447	Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1777.	1.8	12
448	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , 2020, 14, 1093-1103.	1.9	12
449	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1619-1627.	1.4	12
450	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , 2021, 15, 1160-1173.	1.9	12

#	ARTICLE	IF	CITATIONS
451	Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1206-1218.	1.6	12
452	Outcome of Budd-Chiari Syndrome Patients Treated With Direct Oral Anticoagulants: An Austrian Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 978-987.e2.	2.4	12
453	Bilirubin Kinetic Modeling for Quantification of Extracorporeal Liver Support. <i>Blood Purification</i> , 2006, 24, 413-422.	0.9	11
454	Comparative Analysis and Modeling of the Severity of Steatohepatitis in DDC-Treated Mouse Strains. <i>PLoS ONE</i> , 2014, 9, e111006.	1.1	11
455	Therapeutic Potential of and Treatment with Boceprevir/Telaprevir-Based Triple-Therapy in HIV/Chronic Hepatitis C Co-Infected Patients in a Real-World Setting. <i>AIDS Patient Care and STDs</i> , 2014, 28, 221-227.	1.1	11
456	Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice. <i>BioMed Research International</i> , 2016, 2016, 1-7.	0.9	11
457	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 309-316.	0.8	11
458	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 2578-2586.	0.7	11
459	Pulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 467-468.	1.4	11
460	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 335-344.	1.3	11
461	Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 610-622.	0.7	11
462	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , 2022, 54, 500-508.	0.4	11
463	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , 2022, 57, 99-110.	2.3	11
464	The role of the hepatocyte cytokeratin network in bile formation and resistance to bile acid challenge and cholestasis in mice. <i>Hepatology</i> , 2009, 50, 893-899.	3.6	10
465	Nuclear receptor ligands in therapy of cholestatic liver disease. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 4299.	3.0	10
466	Adiponectin, bile acids, and burnt-out nonalcoholic steatohepatitis: New light on an old paradox. <i>Hepatology</i> , 2013, 57, 2106-2109.	3.6	10
467	Epidemiological Trends of Hepatocellular Carcinoma in Austria. <i>Digestive Diseases</i> , 2014, 32, 664-669.	0.8	10
468	Response-Guided Boceprevir-based Triple Therapy in HIV/HCV-coinfected Patients: The HIVCOBOC-RGT Study. <i>Journal of Infectious Diseases</i> , 2015, 211, 729-735.	1.9	10

#	ARTICLE	IF	CITATIONS
469	Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. <i>Molecular Endocrinology</i> , 2015, 29, 1320-1333.	3.7	10
470	The trigger matters – outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , 2016, 36, 1649-1656.	1.9	10
471	Endoscopic versus surgical management of biliary complications – Outcome analysis after 1188 orthotopic liver transplantations. <i>Digestive and Liver Disease</i> , 2016, 48, 1323-1329.	0.4	10
472	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , 2019, 14, e0224506.	1.1	10
473	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , 2019, 33, 197-206.	1.1	10
474	On the Mechanisms of Biliary Flux. <i>Hepatology</i> , 2021, 74, 3497-3512.	3.6	10
475	Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19. <i>Journal of Personalized Medicine</i> , 2021, 11, 1264.	1.1	10
476	The –Viennese epidemic–™ of acute HCV in the era of direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2022, 29, 385-394.	1.0	10
477	IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH. <i>Hepatology</i> , 2023, 77, 20-32.	3.6	10
478	Animal models of biliary tract injury. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 239-243.	1.0	9
479	Serum bile acids in patients with hepatopulmonary syndrome. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 361-367.	0.2	9
480	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , 2017, 129, 517-526.	1.0	9
481	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2164-2172.	1.4	9
482	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , 2020, 2, 100060.	2.6	9
483	Lysosomal acid lipase is the major acid retinyl ester hydrolase in cultured human hepatic stellate cells but not essential for retinyl ester degradation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2020, 1865, 158730.	1.2	9
484	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. <i>FASEB Journal</i> , 2021, 35, e21217.	0.2	9
485	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 90-102.e6.	2.4	9
486	Ursodeoxycholic Acid for Treatment of Fatty Liver Disease and Dyslipidemia in Morbidly Obese Patients. <i>Digestive Diseases</i> , 2011, 29, 117-118.	0.8	8

#	ARTICLE	IF	CITATIONS
487	Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. <i>Digestion</i> , 2015, 91, 286-293.	1.2	8
488	A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection. <i>Endoscopy International Open</i> , 2015, 03, E19-E28.	0.9	8
489	Long-term follow-up of ribavirin-free <sc>DAA</sc>-based treatment in <sc>HCV</sc> recurrence after orthotopic liver transplantation. <i>Liver International</i> , 2018, 38, 1188-1197.	1.9	8
490	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3642-3651.	1.1	8
491	Towards a nationwide implementation of a standardized nutrition and dietetics terminology in clinical practice: a pre-implementation focus group study including a pretest and using the consolidated framework for implementation research. <i>BMC Health Services Research</i> , 2019, 19, 920.	0.9	8
492	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , 2020, 12, 2961.	1.7	8
493	Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?. <i>Nutrients</i> , 2020, 12, 765.	1.7	8
494	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Hepatology Communications</i> , 2021, 5, 1939-1952.	2.0	8
495	Proteomic Changes of Activated Hepatic Stellate Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12782.	1.8	8
496	Gadoxetic acid-enhanced MRI-derived functional liver imaging score (FLIS) and spleen diameter predict outcomes in ACLD. <i>Journal of Hepatology</i> , 2022, 77, 1005-1013.	1.8	8
497	Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. <i>American Journal of Gastroenterology</i> , 1998, 93, 1985-1986.	0.2	7
498	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2016, 30, 2879-2885.	1.3	7
499	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoxetic Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-9.	0.4	7
500	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , 2019, 7, 651-661.	1.6	7
501	Intraoperative Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , 2022, 122, 353-362.	1.8	7
502	Histone deacetylase 1 controls CD4+ T cell trafficking in autoinflammatory diseases. <i>Journal of Autoimmunity</i> , 2021, 119, 102610.	3.0	7
503	New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. <i>United European Gastroenterology Journal</i> , 2021, 9, 947-954.	1.6	7
504	Modern imaging of cholangitis. <i>British Journal of Radiology</i> , 2021, 94, 20210417.	1.0	7

#	ARTICLE	IF	CITATIONS
505	Direct patient-physician communication via a hepatitis hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 452-460.	1.0	7
506	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 1485-1493.	1.8	7
507	Long-Term Outcome of HBV-Infected Patients with Clinically Significant Portal Hypertension Achieving Viral Suppression. <i>Journal of Personalized Medicine</i> , 2022, 12, 239.	1.1	7
508	Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2 ^{-/-} mouse model of sclerosing cholangitis via immunomodulatory effects. <i>Hepatology Communications</i> , 2022, 6, 2368-2378.	2.0	7
509	Hepatocellular Bile Salt Transport: Lessons from Cholestasis. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2000, 14, 99D-104D.	1.8	6
510	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 2002, 18, 314-329.	1.0	6
511	Combined Rifampicin and Ursodeoxycholic Acid Treatment Does Not Amplify Rifampicin Effects on Hepatic Detoxification and Transport Systems in Humans. <i>Digestion</i> , 2012, 86, 244-249.	1.2	6
512	Hepatobiliary transporter expression and postoperative jaundice in patients undergoing partial hepatectomy. <i>Liver International</i> , 2012, 32, 119-127.	1.9	6
513	Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis. <i>Clinical Liver Disease</i> , 2017, 9, 43-47.	1.0	6
514	Hepatocyte specific expression of an oncogenic variant of β -catenin results in lethal metabolic dysfunction in mice. <i>Oncotarget</i> , 2018, 9, 11243-11257.	0.8	6
515	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , 2019, 9, 11674.	1.6	6
516	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , 2020, 52, 1473-1479.	0.4	6
517	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. <i>Annals of Internal Medicine</i> , 2021, 174, 139-140.	2.0	6
518	Acute hemodynamic response to propranolol predicts bleeding and nonbleeding decompensation in patients with cirrhosis. <i>Hepatology Communications</i> , 2022, 6, 2569-2580.	2.0	6
519	Strategies for Assignment of HIV-HCV Genotype-1-Coinfected Patients to Either Dual-Therapy or Direct-Acting Antiviral Agent-Based Triple-Therapy. <i>Antiviral Therapy</i> , 2014, 19, 407-414.	0.6	5
520	Sulphatation Does Not Appear to Be a Protective Mechanism to Prevent Oxysterol Accumulation in Humans and Mice. <i>PLoS ONE</i> , 2013, 8, e68031.	1.1	5
521	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [18F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 106-112.	1.6	5
522	Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?. <i>Hepatology</i> , 2017, 65, 1758-1761.	3.6	5

#	ARTICLE	IF	CITATIONS
523	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. <i>Oncotarget</i> , 2017, 8, 57109-57120.	0.8	5
524	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	5
525	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 4391-4404.	2.4	5
526	Management of patients with chronic hepatitis C failing repeated courses of interferon-free direct acting antiviral combination therapy. <i>GastroHep</i> , 2019, 1, 76-83.	0.3	5
527	Alpha-fetoprotein-adjusted HCC size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , 2021, 9, 209-219.	1.6	5
528	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , 2021, 11, 281.	1.1	5
529	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , 2021, 10, 48.	1.7	5
530	Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 5693-5703.	1.1	5
531	The Tyrosine Kinase Tec Regulates Effector Th17 Differentiation, Pathogenicity, and Plasticity in T-Cell-Driven Intestinal Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 750466.	2.2	5
532	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2712-2718.	1.1	4
533	Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies. <i>Journal of Hepatology</i> , 2020, 73, S105.	1.8	4
534	Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 69-79.	1.8	4
535	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 421-431.	1.0	4
536	Characterization of endogenous bile acid composition in individuals with cold-activated brown adipose tissue. <i>Molecular and Cellular Endocrinology</i> , 2021, 536, 111403.	1.6	4
537	KIAA1363 affects retinyl ester turnover in cultured murine and human hepatic stellate cells. <i>Journal of Lipid Research</i> , 2022, 63, 100173.	2.0	4
538	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. <i>Advances in Medical Sciences</i> , 2022, 67, 154-162.	0.9	4
539	Clinical-Pathological Conference Series from the Medical University of Graz. <i>Wiener Klinische Wochenschrift</i> , 2006, 118, 769-775.	1.0	3
540	Animal Models of Cholestasis. , 2013, , 331-349.		3

#	ARTICLE	IF	CITATIONS
541	A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 924-929.	0.5	3
542	[11C]acetate PET as a tool for diagnosis of liver steatosis. <i>Abdominal Radiology</i> , 2018, 43, 2963-2969.	1.0	3
543	THU-023-Monoacylglycerol lipase inhibition protects from hepatic inflammation and fibrosis in mouse models of sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, e170.	1.8	3
544	In Vivo 1H MRSpectroscopy of Biliary Components of Human Gallbladder at 7T. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 98-107.	1.9	3
545	Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2126.	1.8	3
546	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , 2021, 41, 2622-2634.	1.9	3
547	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , 1999, 15, 217-228.	1.0	3
548	Alterations of hepatobiliary transporter expression in primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , 2002, 36, 28-29.	1.8	2
549	Mycosis as a Cause of Secondary Sclerosing Cholangitis Requiring Liver Replantation. <i>Transplantation</i> , 2011, 91, e14-e16.	0.5	2
550	Chromosomal instability in HCC: a key function for checkpoint kinase 2. <i>Gut</i> , 2018, 67, 204-205.	6.1	2
551	Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorus-31 Magnetic Resonance Spectroscopy Pilot Study. <i>Journal of Magnetic Resonance Imaging</i> , 2021, , .	1.9	2
552	Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension. <i>Digestive and Liver Disease</i> , 2022, 54, 1222-1229.	0.4	2
553	Abnormal hepatic sinusoidal bile acid transport: New insights into the pathogenesis of cholestasis?. <i>Gastroenterology</i> , 2001, 120, 321-322.	0.6	1
554	Editorial for "Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis". <i>Liver International</i> , 2014, 34, 328-329.	1.9	1
555	Reply. <i>Hepatology</i> , 2016, 63, 346-347.	3.6	1
556	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , 2016, 48, 1194-1199.	0.4	1
557	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 414-420.	1.0	1
558	Effective medical treatments for PSC needed ASAP - is AESOP the answer?. <i>Journal of Hepatology</i> , 2020, 73, 12-14.	1.8	1

#	ARTICLE	IF	CITATIONS
559	Acquired Alterations of Transporter Expression and Function in Cholestasis. , 2004, , 266-288.		1
560	Cholestatic syndromes. Current Opinion in Gastroenterology, 2000, 16, 239-250.	1.0	0
561	A4.6â€¦Effects of Cholic Acid and its Derivatives in Experimental Arthritis. Annals of the Rheumatic Diseases, 2013, 72, A25.2-A26.	0.5	0
562	Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth, <i>Clostridium difficile</i> infection and polymyalgia rheumatica. BMJ Case Reports, 2016, 2016, bcr2015213465.	0.2	0
563	IDDF2019-ABS-0131â€¦Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials. , 2019, , .		0
564	IDDF2019-ABS-0133â€¦Routinely available noninvasive tests discriminate advanced fibrosis due to NASH in the phase 3 STELLAR trials of the ASK1 inhibitor selonsertib. , 2019, , .		0
565	EASL Recognition Award Recipient 2020: Prof. James L. Boyer. Journal of Hepatology, 2020, 73, 487-489.	1.8	0
566	Reply. Hepatology, 2020, 72, 1498-1499.	3.6	0
567	Reply to: â€œChallenges in understanding the consequences of variants in ABCB4 geneâ€œ. Journal of Hepatology, 2021, 74, 244-245.	1.8	0
568	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. Digestive and Liver Disease, 2021, 53, 345-352.	0.4	0
569	PrimÃr biliÃre Cholangitis (PBC). , 2021, , 368-376.		0
570	O24â€¦Durability of obeticholic acid response in PBC patients who did not achieve poise trial criteria. , 2021, , .		0
571	Alan Hofmann (1931â€2021): A career well spent understanding bile acids. Hepatology, 2022, 75, 238-239.	3.6	0
572	A life with bile acids: Alan F. Hofmann (1931-2021). Journal of Hepatology, 2021, 75, 1265-1266.	1.8	0
573	Bile Acids and Their Receptors. , 2010, , 317-332.		0
574	HepatobiliÃre FunktionsstÃrungen und Lebersagen. , 2011, , 567-578.		0
575	Primary Sclerosing Cholangitis (PSC). , 2014, , 301-316.		0
576	Bile Acids and Bilirubin in Liver Immunology. , 2020, , 103-124.		0

#	ARTICLE	IF	CITATIONS
577	S0984â€fLong-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. American Journal of Gastroenterology, 2020, 115, S501-S502.	0.2	0
578	Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by other Nuclear Receptors. , 0, , 275-300.		0
579	Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. Journal of Clinical Medicine, 2022, 11, 2863.	1.0	0